If the FDA ultimately issues a final determination against listing, compounders would lose any viable legal pathway and substances could be re-nominated in future PCAC cycles, or challenged in court, as happened with previously restricted peptides
Delivery across Ukraine 12 days in thermal box (cold chain 28C)
Both remain under Category 2 restrictions
However, the absence of large-scale human trials, FDA approval, and standardized sourcing means that patients should proceed with caution
Kocken, C.H.M., Narum, D.L., Massougbodji, A., Ayivi, B., Dubbeld, M.A., van der Wel, A., Conway, D.J., Sanni, A
Our small-batch synthesis process ensures impeccable quality control, and every batch is subjected to rigorous third-party testing to verify its identity and purity is above 99%